You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR ENALAPRILAT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for enalaprilat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00226096 ↗ Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Completed National Health and Medical Research Council, Australia N/A 2005-11-01 The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00226096 ↗ Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Completed The George Institute N/A 2005-11-01 The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00741156 ↗ The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed The Hospital for Sick Children Phase 3 2008-07-01 The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
NCT01324245 ↗ Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet Completed University of Virginia N/A 2002-11-01 The kidney plays a crucial role in maintaining salt balance by two opposing physiological mechanisms: the renal dopaminergic system which enhances salt excretion and the renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension occurs when this balance is altered or abnormal. We hypothesized that this balance is influenced by salt intake: therefore dietary salt affects the natriuretic response to the renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor, Enalapril. In this trial we study normal salt balance mechanisms in salt resistant adults with normal blood pressure.
NCT01324245 ↗ Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet Completed Georgetown University N/A 2002-11-01 The kidney plays a crucial role in maintaining salt balance by two opposing physiological mechanisms: the renal dopaminergic system which enhances salt excretion and the renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension occurs when this balance is altered or abnormal. We hypothesized that this balance is influenced by salt intake: therefore dietary salt affects the natriuretic response to the renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor, Enalapril. In this trial we study normal salt balance mechanisms in salt resistant adults with normal blood pressure.
NCT01413542 ↗ Pharmacogenetics of Ace Inhibitor-Associated Angioedema Completed Vanderbilt University N/A 2011-11-01 The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for enalaprilat

Condition Name

Condition Name for enalaprilat
Intervention Trials
Heart Failure 3
Hypertension 2
Congestive Cardiomyopathy 1
Salt-sensitive Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for enalaprilat
Intervention Trials
Hypertension 4
Heart Failure 3
Cardiomyopathy, Dilated 2
Cardiomyopathies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for enalaprilat

Trials by Country

Trials by Country for enalaprilat
Location Trials
Australia 5
United States 4
Netherlands 2
Hungary 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for enalaprilat
Location Trials
Tennessee 2
Maryland 1
District of Columbia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for enalaprilat

Clinical Trial Phase

Clinical Trial Phase for enalaprilat
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for enalaprilat
Clinical Trial Phase Trials
Completed 7
Unknown status 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for enalaprilat

Sponsor Name

Sponsor Name for enalaprilat
Sponsor Trials
Ethicare GmbH 3
Vanderbilt University 2
National Health and Medical Research Council, Australia 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for enalaprilat
Sponsor Trials
Other 16
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.